Thu, 15th Dec 2022 07:49
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Both companies said they would continue to work with the FDA to facilitate the completion of the agency's review.
(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.
PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly ...
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...
FTSE 100 up 0.5%, FTSE 250 adds 0.4% *
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...
Astrazeneca (AZN)